Hospital General Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  2. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

2023

  1. Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry (Arthritis Research & Therapy, (2023), 25, 1, (86), 10.1186/s13075-023-03045-3)

    Arthritis Research and Therapy

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  4. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 115-124

  5. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

  6. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 500-506

  7. Screening criteria for interstitial lung disease associated to rheumatoid arthritis: Expert proposal based on Delphi methodology

    Reumatologia Clinica, Vol. 19, Núm. 2, pp. 74-81

2022

  1. Correction to: Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry (Rheumatology and Therapy, (2022), 9, 4, (1031-1047), 10.1007/s40744-022-00446-9)

    Rheumatology and Therapy

  2. Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry

    Rheumatology and Therapy, Vol. 9, Núm. 4, pp. 1031-1047